HYPERTENSION MANAGEMENT IN ELDERLY POPULATIONS
|
|
- Noah Hoover
- 5 years ago
- Views:
Transcription
1 HYPERTENSION MANAGEMENT IN ELDERLY POPULATIONS Michael J. Scalese, PharmD, BCPS, CACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 14, 2018
2 DISCLOSURE/CONFLICT OF INTEREST I, Michael J. Scalese, have no actual or potential conflict of interest in relation to this program
3 OBJECTIVES 1. Discuss the impact of antihypertensives in older persons 2. Compare and contrast current guideline recommendations for the treatment of hypertension in adults 60 years of age 3. Develop an evidence-based treatment plan for older persons with hypertension
4 HYPERTENSION IN THE ELDERLY Elderly population is the largest growing demographic Large economic implications Expected to make up 50% of population by 2060 As of 2018, more than 80% of people 65 years have hypertension
5 CV DEATHS IN ALABAMA Alabama CVD deaths 294 deaths/100k people 2 nd highest in the US (rank 51/52) Alabama Stroke related deaths 48.6 deaths/100k people Highest in the US (rank 52/52) Impacts men more than women Circulation. 2017;135:
6 HYPERTENSION IN THE ELDERLY May present differently than younger populations Psuedo-resistant or resistant HTN Noncompliance with medications Isolated systolic hypertension Much more common in elderly population Tight vs Lenient BP control Fall risk and Frailly
7 Goal Blood Pressure for the Elderly
8 PATIENT CASE-KM KM is a 71 year old Chinese female with no significant medial history. She was diagnosed with essential hypertension 6 months ago and has implemented lifestyle modifications. KM has been referred to your clinic today for pharmacologic management of her high blood pressure after incomplete success of diet, exercise, and other life style changes. Her BP readings at her visit today are 156/92 and 152/90 What is KM s blood pressure goal? A. <120/80 B. <130/80 C. <140/90 D. <150/90
9 JNC8 RECOMMENDATIONS General population > 60 years Blood pressure target < 150/90 mmhg reduces stroke, HF, CHD SBP < 140 mmhg not recommended No additional benefit vs higher goal 2 underpowered Japanese studies JATOS, VALISH JAMA 2014;311(5): NEJM 2008;358(8): Lancet 1997;350(9080): JAMA 1991;265(24):
10 JNC8 EVIDENCE: ELDERLY BP TARGET Trial Age Intervention Primary Endpoint Result HYVET 2008 Syst-Eur 1997 SHEP 1991 > 80 years > 60 years > 60 years Indapamide vs. placebo Nitrendipine vs. placebo Chlorthalidone vs. placebo Indapamide reduces fatal stroke Nitrendipine reduces fatal and nonfatal stroke Chlorthalidone reduces fatal and nonfatal stroke Mean SBP (mmhg) 2 years: 144 vs years: 150 vs years: 143 vs. 155 JAMA 2014;311(5): NEJM 2008;358(8): Lancet 1997;350(9080): JAMA 1991;265(24):
11 CLINICAL CONTROVERSIES THE MINORITY VIEW JNC8 5 of 17 panel members disagreed with elderly BP goal JNC 8 recommendation missing sufficient evidence Concern for reducing intensity of antihypertensive therapy in high risk population Higher BP goal may reverse CVD and stroke benefit SBP goal of < 140 mmhg, especially in high risk population Supported by observational studies and RCT data Support SBP < 150 mmhg in frail patients > 80 years old Similar to European guideline recommendations Ann Intern Med. 2014;160(7):
12 HYVET 3845 hypertensive patients > 80 years old and SBP > 160 mmhg Indapamide SR 1.5 mg vs placebo Perindopril 2-4 mg or placebo added if necessary to achieve SBP < 150 mmhg Median follow-up: 1.8 years Primary endpoint (fatal or nonfatal stroke) Lower but not significantly reduced with indapamide (12.4% vs. 17.7%) Fatal stroke was significantly reduced (p=0.046) Seated blood pressure after 2 years 143.5/77.9 mmhg indapamide vs 158.5/84 mmhg placebo NEJM 2008;358(8):
13 JATOS (2008) & VALISH (2010) JATOS VALISH 2 year duration 3 year duration Patients years of age Goal SBP <140mmHg vs <160mmHg No difference in CVD or renal outcomes (primary outcome) No difference in All-cause mortality (secondary outcome) Patients years of age with isolated systolic hypertension Goal SBP <140mmHg vs <150mmHg No difference in CV morbidity or mortality Study underpowered Study underpowered Major type II error Major type II error Ann Intern Med. 2014;160(7): Hypertens Res. 2008;31: Hypertension. 2010;56:
14 FEVER (EXCLUDED FROM JNC-8) Investigator-designed, prospective, multicenter, double-blind, randomized, placebo-controlled, parallel group trial 9800 Chinese patients years of age with BP /90-100mmHg 1-2 additional CV risk factors All patients on low dose thiazide Addition of low dose felodipine ER vs placebo Median 40 month follow up BP 137.3/82.5mmHg vs 142.5/85mmHg respectively Incidence of stroke reduced in felodipine group (P =0.001) (primary outcome) Secondary outcomes also significantly reduced (CV events, all cause mortality, coronary events, heart failure) J Hypertens Dec;23(12):
15 JNC-8 ELDERLY PATIENT BOTTOM LINE Higher BP target in age range not supported by evidence 2 Japanese only studies underpowered FEVER trial excluded Sufficient evidence to support rise in SBP target to <150 in patients 80 years old Especially in Isolated systolic hypertension Strong support from HYVET & SHEP In this case, majority doesn t rule Minority report highlights significant limitations to JNC-8 recommendations JAMA 2014;311(5): NEJM 2008;358(8): Lancet 1997;350(9080): JAMA 1991;265(24): Ann Intern Med. 2014;160(7): Hypertens Res. 2008;31: Hypertension. 2010;56:
16 PATIENT CASE REVISITED-KM KM is a 71 year old Chinese female with no significant medial history. She was diagnosed with essential hypertension 6 months ago and has implemented lifestyle modifications. KM has been referred to your clinic today for pharmacologic management of her high blood pressure after incomplete success of diet, exercise, and other life style changes. Her BP readings at her visit today are 156/92 and 152/90 Based on JNC-8 and the minority report, what is KM s blood pressure goal? A. <120/80 B. <130/80 C. <140/90 D. <150/90
17 ACP GUIDELINES 2017 HTN TREATMENT IN ADULTS > 60 YEARS Adults > 60 years History of stroke High CV risk SBP goal < 150 mmhg to reduce mortality, stroke, and cardiac events Consider SBP goal < 140 mmhg to reduce recurrent stroke Consider SBP goal < 140 mmhg to reduce stroke or cardiac events Ann Intern Med 2017 Mar 21;166(6):
18 2017 GUIDELINES (ACC/AHA/AAPA/ABC/ACPM/AGS/APHA/ ASH/ASPC/NMA/PCNA) Joint guideline supported by many interdisciplinary organizations 24 member development panel reviewed >900 clinical studies Paradigm shift in blood pressure targets to much more strict goals BP >130/80 now stage I HTN prevalence of HTN in US by 14% Treat if elevated CV risk or history of CV event BP >140/90 now stage II HTN Treat all patients with 1 drug Consider 2 agents if significantly elevated or if 1 agent unlikely to get patient to goal Inclusion of ASCVD Risk Assessment to guide treatment strategies J Am Col Cardiol 2018 ;71(19):
19 POOLED COHORT EQUATIONS ASCVD RISK ESTIMATOR Developed from 5 major cohorts ARIC, CHS, CARDIA, Framingham Cohort, and Offspring Validated in MESA & REGARDS studies Age years with No ASCVD, AF, or HF at baseline Designed for primary prevention patients NOT on drug therapy Very few patients in cohorts were on lipid lowering therapy Provides 2 different risk assessments 10 year risk of hard ASCVD Lifetime risk for someone age 50 yrs
20 ASCVD CALCULATION-KM KM is 71 year old Chinese female with no significant past medical history Vitals: BP 154/91 (average of todays readings), HR 74, RR 16 Medications: Daily Multi-vitamin Social History: denies tobacco, occasional alcohol, no illicit drugs Family history: Mother had a stroke at age 79 Labs: TC=190 mg/dl TG=205 mg/dl HDL=30 mg/dl LDL-C =119 mg/dl What is KM s 10-year ASCVD risk? A. 15.0% B. 15.9% C. 16.2% D. 21.1%
21 POOLED COHORT EQUATIONS ASCVD RISK ESTIMATOR Incorporates ASCVD Risk Factors: Age Sex Race Systolic blood pressure Total Cholesterol HDL Diabetes Smoking status Current hypertension treatment
22 POOLED COHORT EQUATIONS ASCVD RISK ESTIMATOR Applies best to AA or C of either sex Limitations Overestimates risk for Eastern Asian (Chinese, Japanese, Vietnamese, or Korean), Hispanics Underestimates risk for: Native Americans, Pacific Islanders, and individuals of South Asian ancestry, defined as those of Indian, Pakistani, or Bangladeshi descent If applied should classify these individuals as Caucasian or other Only incudes data for people aged (10 yr); (lifetime)
23 2017 GUIDELINES- ELDERLY POPULATION (ACC/AHA/AAPA/ABC/ACPM/AGS/APHA/ ASH/ASPC/NMA/PCNA) Goal to CV/stroke risk & prevent harm (falls, AE s, orthostasis, etc) No evidence of orthostasis or injury in community dwelling older adults in multiple trials renal injury with tighter control but risk was the same as in younger populations Use caution if frequent falls, cognitive impairment, or multiple comorbidities BP recommendation parallels general population (BP <130/80) focus on ASCVD risk assessment 88% of patients 65 years have >10% ASCVD risk or clinical ASCVD 100% of patients 75 years have >10% ASCVD risk or clinical ASCVD Recommendation relied heavily on HYVET and SPRINT trials J Am Col Cardiol 2018 ;71(19):
24 SPRINT Randomized, controlled, multicenter, open-label trial 9361 patients with SBP > 130 mmhg, high CV risk, no diabetes Intervention SBP < 120 mmhg vs. SBP < 140 mmhg Primary outcome MI, other ACS, stroke, heart failure, CV death NEJM 2015;373(22):
25 SPRINT Mean follow-up: 3.26 years (terminated early) Intensive treatment significantly reduced primary endpoint (5.5% vs. 6.5%, p<0.001) Mean SBP achieved mmhg vs mmhg respectively Mean number of medications: 2.8 vs. 1.8 Subgroup analysis Potentially better results in those > 75 years, mean 79.9 years NEJM 2015;373(22):
26 SPRINT-ELDERLY SUBGROUP Primary outcome MI, other ACS, stroke, heart failure, CV death 7.74% (intensive) vs. 11.2% (standard), p=0.001(nnt=29) Significant reduction in HF and all-cause mortality No difference in adverse effects Hypotension Syncope Electrolyte abnormalities AKI/renal failure JAMA 2016;315(24):
27 2016 SYSTEMATIC REVIEW AND META-ANALYSIS Evaluated safety & efficacy of intensive BP in high risk patients 19 RCTs comparing BP targets or intensity of treatment Intensive lowering (mean BP 133/76 mmhg vs. 140/81 mmhg in less intensive groups) Reduces major CV events, MI, stroke, albuminuria, retinopathy Minimal difference in serious adverse events Sub-group of 7 trials with mean age > 62 years significant reduction in major CV events Lancet 2016; 387:
28 2017 SYSTEMATIC REVIEW AND META-ANALYSIS -RESULTS High-strength evidence from 9 trials BP < 150/90 mmhg reduces mortality, cardiac events, and stroke Low- to moderate-strength evidence from 6 trials BP < 140/85 mmhg Reduces cardiac events and stroke No reduction in mortality Results largely weighted by SPRINT No increase in falls or cognitive impairment Ann Intern Med. 2017;166(6):
29 PATIENT CASE REVISITED.AGAIN KM is a 71 year old Chinese female with no significant medial history. She was diagnosed with essential hypertension 6 months ago and has implemented lifestyle modifications. KM has been referred to your clinic today for pharmacologic management of her high blood pressure after incomplete success of diet, exercise, and other life style changes. Her BP readings at her visit today are 156/92 and 152/90 Based on everything we now know, what is KM s blood pressure goal? A. <120/80 B. <130/80 C. <140/90 D. <150/90
30 PATIENT CASE REVISITED.AGAIN KM is a 71 year old Chinese female with no significant medial history. She was diagnosed with essential hypertension 6 months ago and has implemented lifestyle modifications. KM has been referred to your clinic today for pharmacologic management of her high blood pressure after incomplete success of diet, exercise, and other life style changes. Her BP readings at her visit today are 156/92 and 152/90 What medication should we initiate for KM? A. Atenolol 25mg by mouth daily B. Chlortalidone 12.5mg by mouth daily C. Fosinopril 10mg by mouth daily D. Verapamil SR 120mg by mouth twice daily
31 Medications in the Elderly
32 GENERAL CONSIDERATIONS FOR MEDICATION SELECTION Presence of comorbidities Isolated Systolic Hypertension (ISH) vs combined hypertension Orthostatic risk with medications & patient frailty One medication vs multiple Use combination products when possible/available First line options to consider Thiazides Long-acting calcium channel blockers ACE/ARB s Medication choice less important than reaching BP goal
33 THIAZIDES/THIAZIDE-LIKE DIURETICS Most effective BP lowering in elderly Drug of choice in isolated systolic hypertension Strong evidence from SHEP/HYVET May be preferred over ACE/ARB in essential hypertension Reduction of CV events in post-hoc subgroup of ALLHAT Well tolerated in older population Lancet 1997; 350:757 JAMA 2002; 288:2981 Lancet 1999; 354:1751 NEJM 2008;358(8):
34 CALCIUM CHANNEL BLOCKERS Dihydropyridine preferred over non-dihydropyridines Effective antihypertensive in the older population Especially in isolated systolic hypertension Supported by elderly subgroups in FEVER, ALLHAT, Syst-Eur trial, STOP Hypertension-2, Syst-China, & ACCOMPLISH trials Good evidence for use as part of combo therapy regimen Limited side effects in elderly as compared to general population Low risk of orthostasis Lancet 1997; 350:757 J Hypertens 1998; 16:1823 JAMA 2002; 288:2981 Lancet 1999; 354:1751 N Engl J Med 2008; 359:2417
35 ARB/ARB First line agent but less preferred than CCB s and thiazides May be slightly less potent antihypertensives Some side effects more common in elderly 1 st dose hypotension Orthostasis Caution with renal function Especially with lower BR target in new guidelines Use cautiously in AA population May not be as big of a deal as we once thought JAMA 2002; 288:2981 Lancet 1999; 354:1751 NEJM 2008;358(8):
36 MEDICATIONS TO AVOID (IN ABSENCE OF COMPELLING INDICATION) Beta-blockers High orthostasis risk May increase CV outcomes and increase adverse effects Just say NO to atenolol Clonidine High dizziness & fall risk Rebound hypertension Alpha-2 Class (ex-doxazosin) May increase CV outcomes (Alpha-2 arm terminated early in ALLHAT) Significant orthostasis risk
37 PATIENT CASE REVISITED...AGAIN...AGAIN KM is a 71 year old Chinese female with no significant medial history. She was diagnosed with essential hypertension 6 months ago and has implemented lifestyle modifications. KM has been referred to your clinic today for pharmacologic management of her high blood pressure after incomplete success of diet, exercise, and other life style changes. Her BP readings at her visit today are 156/92 and 152/90 What medication should we initiate for KM? A. Atenolol 25mg by mouth daily B. Chlortalidone 12.5mg by mouth daily C. Fosinopril 10mg by mouth daily D. Verapamil SR 120mg by mouth twice daily
38 TAKE HOME POINTS JNC-8 recommended a more lenient BP goal of <150/90 for patients >60 years Minority of panel disagreed citing unpowered nature of studies and excluded trials Goal <150/90 appropriate for patients> 80 years, unclear target for patients years 2017 multidisciplinary guidelines support stricter goal of <130/80 in elderly population Lower goal reduced CV outcomes and did not increase risk of AE s Emphasis on CV history & ASCVD-10 year risk assessment When treatment is indicated, thiazides, CCB s, and ACE/ARB are preferred agents in elderly patients without compelling indications Individualize treatment plan based on patient-specific risk/benefit
39 HYPERTENSION MANAGEMENT IN ELDERLY POPULATIONS Michael J. Scalese, PharmD, BCPS, CACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 14, 2018
Hypertension Update Clinical Controversies Regarding Age and Race
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
More informationJNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH
JNC 8 -Controversies Sagren Naidoo Nephrologist CMJAH Joint National Committee (JNC) Panel appointed by the National Heart, Lung, and Blood Institute (NHLBI) First guidelines (JNC-1) published in 1977
More informationDISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.
JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I
More informationNew Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant
More informationManagement of Lipid Disorders and Hypertension: Implications of the New Guidelines
Management of Lipid Disorders and Hypertension Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine
More informationManaging Hypertension in 2016
Managing Hypertension in 2016: Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More informationObjectives. Describe results and implications of recent landmark hypertension trials
Hypertension Update Daniel Schwartz, MD Assistant Professor of Medicine Associate Medical Director of Heart Transplantation Temple University School of Medicine Disclosures I currently have no relationships
More informationBlood Pressure Targets: Where are We Now?
Blood Pressure Targets: Where are We Now? Diana Cao, PharmD, BCPS-AQ Cardiology Assistant Professor Department of Clinical & Administrative Sciences California Northstate University College of Pharmacy
More informationTreating Hypertension in 2018: What Makes the Most Sense Today?
Treating Hypertension in 2018: What Makes the Most Sense Today? Daniel Blanchard, MD Professor of Medicine UC San Diego Cardiovascular Center La Jolla, California 1 2 Speaker Disclosures Consultant and/or
More informationThe Latest Generation of Clinical
The Latest Generation of Clinical Guidelines: HTN and HLD Dave Brackett Clinical Guideline Purpose Uniform approach Awareness of key details Diagnosis Treatment Monitoring Evidence based approach Inform
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationWe are delighted to have Dr. Roetzheim with us today to discuss Managing Hypertension in Older Adult Patients.
Richard Roetzheim, MD, MSPH is Professor and Chair, Department of Family Medicine at the University of South Florida Morsani College of Medicine. Dr. Roetzheim has considerable experience leading NIH funded
More informationDisclosures. Hypertension: Nationwide Dilemma. Learning Objectives. What s Currently Recommended? Specific Concerns 3/9/2012
How Should We ACCOMPLISH Good Blood Pressure Control In Our VETS? Disclosures No conflicts of interest to disclose Updates in the Management of HypertensionIn the Elderly Antoine T. Jenkins, Pharm.D.,
More informationHypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic
Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered
More informationHypertension Management: A Moving Target
9:45 :30am Hypertension Management: A Moving Target SPEAKER Karol Watson, MD, PhD, FACC Presenter Disclosure Information The following relationships exist related to this presentation: Karol E. Watson,
More informationHypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute
Hypertension Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute Hypertension 2017 Classification BP Category Systolic Diastolic Normal 120 and 80 Elevated
More informationHypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures
Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, 2015 William C. Cushman, MD Professor, Preventive Medicine, Medicine, and Physiology University
More informationBlood pressure treatment target in diabetes. Should it be <130 mmhg?
Blood pressure treatment target in diabetes Should it be
More informationClinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital
Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8 Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital Objectives Review the Eighth Joint National Committee (JNC
More informationHYPERTENSION IN THE ELDERLY A BALANCED APPROACH. Barry Goldlist October 31, 2014
HYPERTENSION IN THE ELDERLY A BALANCED APPROACH Barry Goldlist October 31, 2014 DISCLOSURE I have not accepted any money for myself from any pharmaceutical company in the 21 st century I have accepted
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationHypertension Controversies: SPRINTing to New Goals
Hypertension Controversies: SPRINTing to New Goals Diana Isaacs, PharmD, BCPS, BC-ADM, CDE Clinical Pharmacy Specialist Cleveland Clinic Lauren Wolfe, PharmD Primary Care Clinical Specialist Cleveland
More informationMANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION
Management of Hypertension: Treatment Thresholds and Medication Selection Robert B. Baron, MD MS Professor and Associate Dean Declaration of full disclosure: No conflict of interest Presentation Goals
More informationHypertension in the Elderly. John Puxty Division of Geriatrics Center for Studies in Aging and Health, Providence Care
Hypertension in the Elderly John Puxty Division of Geriatrics Center for Studies in Aging and Health, Providence Care Learning Objectives Review evidence for treatment of hypertension in elderly Consider
More informationNew Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets
New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of
More informationUnderstanding the importance of blood pressure control An overview of new guidelines: How do they impact daily current management?
Understanding the importance of blood pressure control An overview of new guidelines: How do they impact daily current management? Slides presented during CDMC in Almaty, Kazakhstan on Saturday April 12,
More informationManaging HTN in the Elderly: How Low to Go
Managing HTN in the Elderly: How Low to Go Laxmi S. Mehta, MD, FACC The Ohio State University Medical Center Assistant Professor of Clinical Internal Medicine Clinical Director of the Women s Cardiovascular
More informationUpdate in Hypertension
Update in Hypertension Eliseo J. PérezP rez-stable MD Professor of Medicine DGIM, Department of Medicine UCSF 20 May 2008 Declaration of full disclosure: No conflict of interest (I have never been funded
More informationImplementation of JNC- 8 Hypertension Recommendations: Combining evidence and value-based practice strategies for accountable care
Implementation of JNC- 8 Hypertension Recommendations: Combining evidence and value-based practice strategies for accountable care Shari Bolen MD, MPH MetroHealth/Case Western Reserve University 1 Disclosure
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
PREVENTING CARDIOVASCULAR DISEASE IN WOMEN: Current Guidelines for Hypertension, Lipids and Aspirin Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationManaging Hypertension in 2018
MANAGING HYPERTENSION IN 2018 How Do We Work With Conflicting Data and Conflicting Guidelines? Disclosure No relevant financial relationships Robert B. Baron, MD MS Professor and Associate Dean UCSF School
More informationT. Suithichaiyakul Cardiomed Chula
T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial
More informationModern Management of Hypertension
Modern Management of Hypertension Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Hypertension Prevalence
More informationAPPENDIX D: PHARMACOTYHERAPY EVIDENCE
Página 1 de 7 APPENDIX D: PHARMACOTYHERAPY EVIDENCE Table D1. Outcome Trials of Antihypertensive Agents Study Drug Regimen N Duration Primary Outcomes Remarks Antihypertensive Therapy vs Placebo SHEP 1991
More informationALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic
1 U.S. Department of Health and Human Services National Institutes of Health Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker
More informationThe New Hypertension Guidelines
The New Hypertension Guidelines Joseph Saseen, PharmD Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Disclosure Joseph Saseen reports no conflicts
More informationNew Clinical Trends in Geriatric Medicine. April 8, 2016 Amanda Lathia, MD, MPhil Staff, Center for Geriatric Medicine
New Clinical Trends in Geriatric Medicine April 8, 2016 Amanda Lathia, MD, MPhil Staff, Center for Geriatric Medicine Objectives Review current guidelines for blood pressure (BP) control in older adults
More informationPreventing and Treating High Blood Pressure
Preventing and Treating High Blood Pressure: Finding the Right Balance of Integrative and Pharmacologic Approaches Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Blood Pressure
More informationModern Management of Hypertension: Where Do We Draw the Line?
Modern Management of Hypertension: Where Do We Draw the Line? Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Blood Pressure
More informationIs there a mechanism of interaction between hypertension and dyslipidaemia?
Is there a mechanism of interaction between hypertension and dyslipidaemia? Neil R Poulter International Centre for Circulatory Health NHLI, Imperial College London Daegu, Korea April 2005 Observational
More informationTreating Hypertension in Individuals with Diabetes
Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any
More informationHypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town
Hypertension targets: sorting out the confusion Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town Historical Perspective The most famous casualty of this approach was the
More informationMODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk
MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More informationBlood Pressure LIMBO How Low To Go?
Blood Pressure LIMBO How Low To Go? Joseph L. Kummer, MD, FACC Bryan Heart Spring Conference April 21 st, 2018 Hypertension Epidemiology Over a billion people have hypertension Major cause of morbidity
More information4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?
HYPERTENSION TARGETS: WHAT DO WE DO NOW? MICHAEL LEFEVRE, MD, MSPH PROFESSOR AND VICE CHAIR DEPARTMENT OF FAMILY AND COMMUNITY MEDICINE UNIVERSITY OF MISSOURI 4/4/17 DISCLOSURE: MEMBER OF THE JNC 8 PANEL
More informationHypertension and the SPRINT Trial: Is Lower Better
Hypertension and the SPRINT Trial: Is Lower Better 8th Annual Orange County Symposium on Cardiovascular Disease Prevention Saturday, October 8, 2016 Keith C. Norris, MD, PhD, FASN Professor of Medicine,
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%
More informationALLHAT. ALLHAT Antihypertensive Trial Results by Baseline Diabetic & Fasting Glucose Status
ALLHAT Antihypertensive Trial Results by Baseline Diabetic & Fasting Glucose Status 1 Introduction and Background Clinical trials have reported reduction in CV events with diuretics, CCBs, ACE inhibitors,
More informationALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial
1 ALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial Davis BR, Piller LB, Cutler JA, et al. Circulation 2006.113:2201-2210.
More informationHypertension and Diabetes Should we be SPRINTING or Reaching an ACCORD?
Hypertension and Diabetes Should we be SPRINTING or Reaching an ACCORD? Suzanne Oparil, MD Distinguished Professor of Medicine, Professor of Cell, Developmental and Integrative Biology Director, Vascular
More informationNew Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD
New Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD None Disclosures Objectives Understand trend in blood pressure clinical practice guidelines
More informationRandomized Design of ALLHAT BP Trial
Outcomes in Hypertensive Black and Nonblack Patients Treated with Chlorthalidone, Amlodipine, and Lisinopril* *Wright JT, Dunn JK, Cutler JA et al. JAMA 2005:293:1595-1608. 42,418 High-risk hypertensive
More informationHypertension Pharmacotherapy: A Practical Approach
Hypertension Pharmacotherapy: A Practical Approach Ronald Victor, MD Burns & Allen Chair in Cardiology Director, The Hypertension Center Associate Director, The Heart Institute Hypertension Center 1. 2.
More informationHypertension Update. Sarah J. Payne, MS, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy UNT System College of Pharmacy
Hypertension Update Sarah J. Payne, MS, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy UNT System College of Pharmacy Introduction 1/3 of US adults have HTN More prevalent in non-hispanic
More informationOutcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension
Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension Prof. Massimo Volpe, MD, FAHA, FESC, Chair of Cardiology, Department of Clinical and Molecular Medicine
More informationYuqing Zhang, M.D., FESC Department of Cardiology, Fu Wai Hospital. CAMS & PUMC, Beijing, China
What Can We Learn from the Observational Studies and Clinical Trials of Prehypertension? Yuqing Zhang, M.D., FESC Department of Cardiology, Fu Wai Hospital. CAMS & PUMC, Beijing, China At ARIC visit 4
More information2/10/2014. Hypertension: Highlights of Hypertension Guidelines: Making the Most of Limited Evidence. Issues with contemporary guidelines
Hypertension: 214 Highlights of Hypertension Guidelines: Making the Most of Limited Evidence Michael A, Weber, MD Editor-in-Chief, The Journal of Clinical Hypertension, Professor of Medicine, Division
More informationJared Moore, MD, FACP
Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner
More informationObjectives. JNC 7 Is Nice But What s Up With JNC 8? Why Do We Care? Hypertension Background: Prevalence
JNC 7 Is Nice But What s Up With JNC 8? 37 th Annual CAPA Conference October 4 th 2013 Ignacio de Artola, Jr. M.D. Assistant Professor of Clinical Family Medicine Medical Director, Primary Care Physician
More informationManaging Hypertension in Diabetes Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park.
Managing Hypertension in Diabetes 2015 Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park Case Scenario Mike M is a 59 year old man with type 2 diabetes managed
More informationHypertension Update 2009
Hypertension Update 2009 New Drugs, New Goals, New Approaches, New Lessons from Clinical Trials Timothy C Fagan, MD, FACP Professor Emeritus University of Arizona New Drugs Direct Renin Inhibitors Endothelin
More informationUpdate in Cardiology Pharmacologic Management of Cardiovascular Risk. Christopher C. Roe, MSN, ACNP
Update in Cardiology Pharmacologic Management of Cardiovascular Risk Christopher C. Roe, MSN, ACNP Objectives 1. Verbalize understanding of new pharmacologic guidelines in the treatment of hypertension
More informationTalking about blood pressure
Talking about blood pressure Mrs Khan 56 BP 158/99 BMI 32 Total cholesterol 5.4 (HDL 0.8) HbA1c 43 She has been promising to do more exercise and eat more healthily for the last 2 years but her weight
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
More informationHighlights of the new blood pressure and cholesterol guidelines: A whole new philosophy. Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM
Highlights of the new blood pressure and cholesterol guidelines: A whole new philosophy Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM OSHP 2014 Annual Meeting Oklahoma City, OK April 4, 2014 1 Objectives
More informationRecent Hypertension Guidelines
Recent Hypertension Guidelines Lawrence J. Fine, MD, DrPH, FAHA Division of Cardiovascular Sciences NHLBI/NIH February 19, 2014 Disclosures: Member of Panel Appointed to the Eighth Joint National Committee
More informationApplying the Intricacies of the New Hypertension and Lipid Guidelines to Your Patients
Applying the Intricacies of the New Hypertension and Lipid Guidelines to Your Patients Joe Anderson, PharmD, PhC, BCPS James Nawarskas, PharmD, PhC, BCPS Gretchen Ray, PharmD, PhC, BCACP University of
More informationHypertension and Cardiovascular Disease
Hypertension and Cardiovascular Disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic,
More informationDisclosures. Learning Objectives. Hypertension: a sprint to the finish Ontario Pharmacists Association 1
Disclosures I have no current or past relationships with commercial entities I have received a speaker s fee from the Ontario Pharmacists Association for this learning activity Laura Tsang PharmD Sunnybrook
More informationCedars Sinai Diabetes. Michael A. Weber
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
More informationDiabetes and Hypertension
Diabetes and Hypertension William C. Cushman, MD, FAHA, FACP, FASH Chief, Preventive Medicine, Veterans Affairs Medical Center Professor, Preventive Medicine, Medicine, and Physiology University of Tennessee
More informationBlood Pressure Targets in Diabetes
Stockholm, 29 th August 2010 ESC Meeting Blood Pressure Targets in Diabetes Peter M Nilsson, MD, PhD Department of Clinical Sciences University Hospital, Malmö Sweden Studies on BP in DM2 ADVANCE RCT (Lancet
More information2014 HYPERTENSION GUIDELINES
2014 HYPERTENSION GUIDELINES Eileen M. Twomey, Pharm.D., BCPS 1 Learning Objectives Describe specific blood pressure thresholds at which antihypertensive therapy should be initiated and blood pressure
More informationIsolated Systolic Hypertension in the elderly. Daniel Hayoz Clinique de Médecine Interne HFR-Hôpital Cantonal Fribourg
Isolated Systolic Hypertension in the elderly Daniel Hayoz Clinique de Médecine Interne HFR-Hôpital Cantonal Fribourg Case no 1 Man aged 75, from Kosovo, in CH since 1.5 years Former smoker (45 PY) BP:
More informationDifficult to Treat Hypertension
Difficult to Treat Hypertension According to Goldilocks JNC 8 Blood Pressure Goals (2014) BP Goal 60 years old and greater*- systolic < 150 and diastolic < 90. (Grade A)** BP Goal 18-59 years old* diastolic
More informationWhen Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes
When Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes Kim K. Birtcher, MS, PharmD, AACC, FNLA, CLS, BCPS (AQ-Cardiology), CDE Clinical Professor University of Houston College
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationMacrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?
Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists
More informationHypertension Update. Mayo Clinic 90 th Annual Clinical Reviews November 2 nd and 16 th, 2016
Mayo Clinic 90 th Annual Clinical Reviews November 2 nd and 16 th, 2016 Hypertension Update Vincent J. Canzanello, M.D. Consultant, Division of Nephrology and Hypertension Professor or Medicine College
More informationLipid Panel Management Refresher Course for the Family Physician
Lipid Panel Management Refresher Course for the Family Physician Objectives Understand the evidence that was evaluated to develop the 2013 ACC/AHA guidelines Discuss the utility and accuracy of the new
More informationAtherosclerotic Disease Risk Score
Atherosclerotic Disease Risk Score Kavita Sharma, MD, FACC Diplomate, American Board of Clinical Lipidology Director of Prevention, Cardiac Rehabilitation and the Lipid Management Clinics September 16,
More informationHypertension Management Controversies in the Elderly Patient
Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No
More informationHypertension in Geriatrics. Dr. Allen Liu Consultant Nephrologist 10 September 2016
Hypertension in Geriatrics Dr. Allen Liu Consultant Nephrologist 10 September 2016 Annual mortality (%) Cardiovascular Mortality Rates are Higher among Dialysis Patients 100 10 1 0.1 0.01 0.001 25-34
More information4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for
+ Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics
More information9/18/2017 DISCLOSURES. Consultant: RubiconMD. Research: Amgen, NHLBI OUTLINE OBJECTIVES. Review current CV risk assessment tools.
UW MEDICINE UW MEDICINE UCSF ASIAN TITLE HEALTH OR EVENT SYMPOSIUM 2017 DISCLOSURES Consultant: RubiconMD ESTIMATING CV RISK IN ASIAN AMERICANS AND PREVENTION OF CVD Research: Amgen, NHLBI EUGENE YANG,
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationHypertension: What s new since JNC 7. Harold M. Szerlip, MD, FACP, FCCP, FASN, FNKF
Hypertension: What s new since JNC 7 Harold M. Szerlip, MD, FACP, FCCP, FASN, FNKF Disclosures Spectral Diagnostics Site investigator Eli Lilly Site investigator ACP IM ITE writing committee NBME Step
More informationUpdates in Cardiovascular Recommendations for Diabetic Patients
Updates in Cardiovascular Recommendations for Diabetic Patients Chris Tawwater, Pharm.D., BCPS Clinical Pharmacist, Abilene Regional Medical Center Assistant Professor, Adult Medicine Division Pharmacotherapy
More informationThe earlier BP control the better cardiovascular outcome. Jin Oh Na Cardiovascular center Korea University Medical College
The earlier BP control the better cardiovascular outcome Jin Oh Na Cardiovascular center Korea University Medical College Index Introduction HOPE-3 Trial Sprint Study Summary Each 2 mmhg decrease in SBP
More informationPrevention of Heart Failure: What s New with Hypertension
Prevention of Heart Failure: What s New with Hypertension Ali AlMasood Prince Sultan Cardiac Center Riyadh 3ed Saudi Heart Failure conference, Jeddah, 13 December 2014 Background 20-30% of Saudi adults
More informationPlacebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationEvolving Concepts on Hypertension: Implications of Three Guidelines (JNC 8 Panel, ESH/ESC, NICE/BSH)
Evolving Concepts on Hypertension: Implications of Three Guidelines (JNC 8 Panel, ESH/ESC, NICE/BSH) Sidney C. Smith, Jr. MD, FACC, FAHA, FESC Professor of Medicine/Cardiology University of North Carolina
More informationHypertension Update 2016 AREEF ISHANI, MD MS CHIEF OF MEDICINE MINNEAPOLIS VA MEDICAL CENTER PROFESSOR OF MEDICINE UNIVERSITY OF MINNESOTA
Hypertension Update 2016 AREEF ISHANI, MD MS CHIEF OF MEDICINE MINNEAPOLIS VA MEDICAL CENTER PROFESSOR OF MEDICINE UNIVERSITY OF MINNESOTA Case 1 What should be your BP goal for an elderly (> 75 yrs of
More informationDiversity and HTN: Approaches to optimal BP control in AfricanAmericans
Diversity and HTN: Approaches to optimal BP control in AfricanAmericans Quinn Capers, IV, MD, FACC, FSCAI Assistant Professor of Medicine Associate Dean for Admissions Do Racial Differences Really Exist
More informationHypertension 2015: Recent Evidence that Will Change Your Practice
Hypertension 2015: Recent Evidence that Will Change Your Practice Gerald W. Smetana, M.D. Division of General Medicine Beth Israel Deaconess Medical Center Professor of Medicine Harvard Medical School
More informationInt. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences
Research Article JNC 8 versus JNC 7 Understanding the Evidences Anns Clara Joseph, Karthik MS, Sivasakthi R, Venkatanarayanan R, Sam Johnson Udaya Chander J* RVS College of Pharmaceutical Sciences, Coimbatore,
More information2/9/2017. Financial Disclosures/Unapproved Use. Achieving Harmony in Blood Pressure Guidelines Around the Globe. Roger S. Blumenthal, MD.
Achieving Harmony in Blood Pressure Guidelines Around the Globe Roger S. Blumenthal, MD The Kenneth Jay Pollin Professor of Cardiology Director, The Johns Hopkins Ciccarone Center for the Prevention Of
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Prevalence 29%; Blacks 33.5% About 72.5% treated; 53.5% uncontrolled (>140/90) Risk for poor control: Latinos, Blacks, age 18-44 and 80,
More informationConflicts of Interest. Hypertension Guidelines Have Your Blood Pressure Up? Learning Objectives-Technician. Learning Objectives-Pharmacist
Conflicts of Interest Hypertension Guidelines Have Your Blood Pressure Up? Diana Isaacs, PharmD, BCPS, BC-ADM, has no actual or potential conflicts of interest in relation to this program. Diana Isaacs,
More information